Sitryx Therapeutics Limited
- Address
- 101 Bellhouse Building, Magdalen Centre, The Oxford Science Park
Sponsor Overview
Specializations
Dermatology and Inflammatory Skin Disease
Clinical research is concentrated on atopic dermatitis, with interest in the skin manifestations of chronic inflammatory disease and the clinical features that shape treatment development.
- Atopic dermatitis
- Inflammatory skin responses
- Dermatologic symptom burden
The sponsor’s current programme reflects a focused therapeutic commitment to skin-directed medicine in a condition marked by immune-driven inflammation and persistent cutaneous disease activity.
Immunology and Immune-Mediated Disease
Research activity also centres on immune processes in the skin, including the local immune response associated with atopic dermatitis and related inflammatory pathways.
- Cutaneous immune response
- Immune-mediated inflammation
- Skin immunology
This area of interest aligns with therapeutic development aimed at modifying disease-relevant immune activity in dermatologic settings.
Early Clinical Development
The sponsor’s research landscape includes early-stage clinical evaluation in both healthy participants and people living with atopic dermatitis, supporting investigation of new treatment options in a controlled clinical setting.
- Healthy participant studies
- First-in-human assessment
- Clinical pharmacology
Current activity is directed toward understanding how emerging therapies interact with skin disease biology and tolerability in human participants.
Pharmacokinetics and Treatment Characterisation
Research interests include the clinical characterisation of candidate therapies through pharmacokinetic evaluation and related measures of how a treatment behaves in the body in the context of skin disease.
- Pharmacokinetic profiling
- Safety and tolerability
- Clinical characterisation
These studies support the development of therapies intended for immune-mediated dermatology and provide insight into their clinical suitability for atopic dermatitis.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| A Phase 1, Adaptive, First-in-Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SYX-5219 in Healthy Volunteers and Participants with Atopic Dermatitis |  Bulgaria Denmark Germany Ireland | Not Recruiting |
| Evaluation of SYX-5219 on Immune Response Modulation in Patients with Atopic Dermatitis |  The Netherlands | Not Recruiting |
Data & Insights
This sponsor works with 0 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 7 sites across their trial portfolio.
Therapeutic Focus
- 1.Skin and Connective Tissue Diseases2 trials247 other sponsors
Partnered Research Centres
7 centres- Address
- Zernikedreef 8, 2333 CL Leiden
- Address
- Augustenburger Platz 1, Wedding, 13353 Berlin
- Address
- Theodor-Stern-Kai 7, 60590 Frankfurt
- Address
- Killianstrasse 5, Stuehlinger, 79106 Freiburg im Breisgau
- Address
- Ulitsa Urvich 13, Krasno Selo District, 1612 Sofia
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Sitryx Therapeutics Limited.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.